Geneva, April 20 -- International Clinical Trials Registry received information related to the study (NCT07522697) titled 'Inavolisib for PIK3CA Mutated Advanced Endometrial Cancer: MITO END-4' on April 1.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: National Cancer Institute, Naples

Condition: Endometrial Cancer

Intervention: Drug: Inavolisib

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: May 2026

Target Sample Size: 48

Countries of Recruitment: Italy

To know more, visit https://clinicaltrials.gov/study/NCT07522697

Published by HT Digital Content Services with p...